Braveheart Bio, Inc.
Braveheart Bio, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy on October 15, 2028. There is 1 upcoming event on record.
Cash runway is approximately 33.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 15, 2028 | BHB-1893 Versus Metoprolol for Symptomatic Obstructive Hypertrophic Cardiomyopathy | Trial Milestone | Phase 3 |
Track BRVE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BRVE in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 8, 2026 | Quarterly results filed (8-K) | Earnings | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.